GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Kanabo Group PLC (LSE:KNB) » Definitions » Notes Receivable

Kanabo Group (LSE:KNB) Notes Receivable : £0.00 Mil (As of Jun. 2024)


View and export this data going back to 2017. Start your Free Trial

What is Kanabo Group Notes Receivable?

Kanabo Group's Notes Receivable for the quarter that ended in Jun. 2024 was £0.00 Mil.


Kanabo Group Notes Receivable Historical Data

The historical data trend for Kanabo Group's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kanabo Group Notes Receivable Chart

Kanabo Group Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Notes Receivable
Get a 7-Day Free Trial - - - - -

Kanabo Group Semi-Annual Data
Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Notes Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Kanabo Group Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.


Kanabo Group Notes Receivable Related Terms

Thank you for viewing the detailed overview of Kanabo Group's Notes Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.


Kanabo Group Business Description

Traded in Other Exchanges
N/A
Address
137-139 Brent Street, Churchill House, London, GBR, NW4 4DJ
Kanabo Group PLC is a research and development company engaged in selling a range of THC-Free retail CBD products in the markets and it is in the process of developing medical cannabis products. Its reportable segments include Primary Care and Secondary Care. The Primary Care segment, which derives key revenue, includes Tele pharma services provided by GPS and The Secondary Care segment includes the development and distribution of cannabis-derived medical and wellness products. Geographically company has a presence in the United Kingdom and Israel.

Kanabo Group Headlines

No Headlines